A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

NCT07733947 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Subcutaneous Fat

Interventions

DRUG: CBL-514 Injection
DRUG: 0.9 % sodium chloride

Sponsor

Caliway Biopharmaceuticals Co., Ltd.